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  Clinical and pathological manifestations of diabetic nephropathy in type 2 diabetes 
are diverse, but large-scale pathological studies with long-term observation have been 
limited.  
Methods 
 Kidney biopsy and clinical data were collected retrospectively from 13 centers across 
Japan for 600 patients with Type 2 diabetes. Thirteen pathological findings (nine 
glomerular lesions, two interstitial lesions, and two vascular lesions) were clearly 
defined and scored. 
Results 
 During the observation period, there were 304 composite kidney events (dialysis, 
doubling of Cr, or halving of eGFR), 31 instances of chronic kidney disease (CKD) 
G5D, 76 cardiovascular events, and 73 deaths. The mean observation period was 72.4 
months. The CKD heat map categories for the 600 patients were 103 green or yellow, 
149 orange, and 348 red. Diffuse lesions, polar vasculosis, and subendothelial space 
widening were commonly detected even in the green and yellow category of cases 
(positive cases: diffuse lesion 81.6%, polar vasculosis 42.6%, and subendothelial space 
widening 35.1%). Cox proportional hazards analysis revealed that the presence of 
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nodular lesions, exudative lesions, and mesangiolysis in green and yellow category 
cases were associated with a significantly greater impact on composite kidney events 
after adjustment for clinical risk factors (hazard ratio, 95% confidence interval; nodular 
lesion: 21.1, 5.3–84.6; exudative lesion: 5.1, 1.3–20.3; mesangiolysis: 7.6, 2.0–28.8).  
Conclusions 
 This nationwide kidney biopsy study of 600 cases with type 2 diabetes revealed that 
pathological findings (the presence of nodular lesions, exudative lesions, and 
mesangiolysis) were strong predictors of kidney events in low-risk patients. 
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INTRODUCTION 
  The chronic kidney disease (CKD) heat map, issued as part of the Kidney Disease: 
Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guideline for the 
Evaluation and Management of Chronic Kidney Disease [1], provides a color-coded 
classification that helps predict the prognosis of CKD. This classification is based on 
three factors: the cause of the disease, the level of albumin in urine (albuminuria), and 
the estimated glomerular filtration rate (eGFR). Albuminuria and eGFR are key 
predictive markers for the prognosis of diabetic nephropathy (DN). In agreement with 
this, our previous data clearly showed that increased albuminuria and reduced eGFR 
were strong predictors of kidney events, cardiovascular events, and all-cause mortality 
in Japanese patients with type 2 diabetes [2]. The CKD heat map classification is simple 
and clinically relevant. In addition to this classification, other markers of kidney 
damage and injury can provide further information relevant to CKD prognosis. 
Pathological findings should be a possible additional marker for CKD. 
  The clinical and pathological manifestations of DN in type 2 diabetes are diverse [3] 
[4]. A recent clinical study of DN showed that there were two clinically characterized 
groups in the progression of kidney dysfunction: rapid decliner and non-decliner groups, 
classified on the basis of the speed of decrease of glomerular filtration rate (GFRs) [5]. 
Our previous study indicated that some pathological findings were good predictors for 
kidney events, cardiovascular events, and all-cause mortality [6] [7]. A recent study 
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revealed that advanced diabetic kidney lesions were incidentally detected even in 
normoalbuminuric cases [8]. These clinical and pathological observations of the 
heterogeneity of diabetic kidney disease motivated us to evaluate how pathological 
findings and clinical category could assist in predicting renal events in patients with 
DN. 
  The pathological classification of diabetic nephropathy (DN) by Tervaert et al. was 
systematic and organized, predicting renal outcomes in patients with DN [9-11]. 
However, this classification omitted some important pathological findings, especially in 
regards to glomerular lesions (Supplementary Table). Accordingly, we evaluated as 
many pathological parameters as possible in the present study, with clear definitions and 
standardized scores for each. With the support of the Ministry of Health, Labour and 
Welfare of Japan, we collected kidney biopsy samples on a national scale and 
reevaluated each DN biopsy specimen. We evaluated the additional predictive value of 
pathological findings, including details of glomerular lesions, and revealed valuable and 
specific pathological findings that can predict kidney events in type 2 diabetes patients, 




  Data for 600 biopsy-confirmed type 2 diabetes patients were collected retrospectively 
from 13 centers across Japan. The diagnosis of diabetes was based on the criteria of the 
Japanese Diabetic Society [12]. Patients were classified as having a diabetes if they met 
one of the following criteria: (i) fasting plasma glucose level ≥126 mg/dl (≥7.0 mmol/l); 
(ii) 75-g oral glucose tolerance test 2-h value ≥200 mg/dl (≥11.1 mmol/l); or (iii) casual 
plasma glucose level ≥200 mg/dl (≥11.1 mmol/l). A kidney biopsy was performed for 
patients for whom it was clinically necessary to obtain a precise diagnosis of kidney 
lesions. Typical indications included proteinuria without diabetic retinopathy, hematuria, 
a rapid decline in eGFR, or massive proteinuria with a short duration history of diabetes. 
Biopsy indications for a 50-case series with normo- or microalbuminuria are presented 
in Supplementary Table 2. Patients with other glomerular diseases concomitant with 
DN were excluded from this study. There was no limitation in glomerular number, if the 
following pathological findings were evaluated. Written informed consent was obtained 
from each patient, and this study´s protocol was approved by the medical ethics 
committee of Kanazawa University (Approval No. 1204). 
 
Pathological examinations  
  Biopsy samples were stained with Periodic Acid–Schiff reagent, periodic acid 
methenamine silver, hematoxylin–eosin, and Mallory–Azan or Masson’s Trichrome 
stains and examined by light microscopy. Pathological stages were defined in detail 
from typical pictures [13]. Nine glomerular lesions, two interstitial lesions, and two 
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vascular lesions were defined. The nine glomerular lesions comprised one diffuse lesion 
(mesangial expansion), one nodular lesion (nodular sclerosis), one subendothelial space 
widening (or duplication of the basement membrane), one exudative lesion, one case of 
mesangiolysis/microaneurysm, one peri-hilar neovascularization (or polar vasculosis), 
one global glomerulosclerosis/collapsing glomerular change and ischemic glomerular 
change, one segmental glomerulosclerosis, and one glomerulomegaly. The two 
interstitial lesions were interstitial fibrosis and tubular atrophy, and interstitial cell 
infiltration. The two vascular lesions were arteriolar hyalinosis and intimal thickening. 
Pathologists in each center evaluated all the pathological scoring as described below.  
 
Definitions and scoring for the pathological findings   
 Agreement on the definitions and scoring for all pathological lesions was reached after 
reviewing previous studies of diabetic nephropathy and many face-to-face meetings 
with all the authors over more than two years. The detailed points on each definition 
and score were published as a handbook [13]. Supplementary Table 1 and its legend 
present a simple summary of the definition for each finding, and the scores are shown in 
Table 1.  
IgG deposition in the glomeruli was also evaluated. The score for this was defined as 





  Age, sex, body mass index (BMI), systolic blood pressure (BP), diastolic BP, 
hemoglobin (Hb) A1c, and total cholesterol (T-Cho) were used as baseline clinical 
parameters at the time of the kidney biopsy. eGFR was calculated using the following 
formula [14]:  
eGFR (mL/min/1.73 m2) = 194 × serum creatinine−1.094 × age−0.287  
(For female patients this value was multiplied by 0.739.) 
  HbA1c levels were presented as national glycohemoglobin standardization program 
values according to the recommendations of the Japanese Diabetic Society (9) and 
International Federation of Clinical Chemistry.  
  Based on the classification of chronic kidney disease, albuminuria at baseline was 
categorized as normoalbuminuria (<30 mg/day or /gCr in albuminuria, category A1), 
microalbuminuria (30–300 mg/day or /gCr in albuminuria, category A2), or very high 
and nephrotic albuminuria (≥300 mg/day or /gCr, category A3) [15]. In the patients for 
whom albuminuria was not evaluated, we classified proteinuria as optimal proteinuria 
(<0.15 g/day or /gCr, category A1), mild proteinuria (0.15–0.5 g/day or /gCr, category 
A2), or severe proteinuria (≥0.5 g/day or /gCr, category A3). When results were 
inconsistent, 24-h urinary albumin excretion was prioritized. The eGFR at baseline was 
categorized according to CKD category (categories G1–5). Based on the CKD heat map 
category according to the KDIGO 2012 Clinical Practice Guideline for the Evaluation 
and Management of Chronic Kidney Disease, all cases were categorized into four 
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groups: Green group: low risk, Yellow group: moderately increased risk, Orange group: 
high risk, and Red group: very high risk.  
Outcomes 
  The outcomes for this study were composite kidney events (dialysis, halving of eGFR, 
or doubling of serum Cr), CKD G5D, cardiovascular events (cardiovascular death, 
nonfatal myocardial infarction, coronary intervention, or nonfatal stroke), and all-cause 
mortality. The sources of the outcome data were collected from each center. 
 
Statistical analysis 
  Data are expressed as mean ± SD and (median,interquartile range). Continuous 
variables were compared between groups using the Mann–Whitney U test for 
nonparametric data, and categorical variables using the chi-square test. Survival curves 
were obtained using the Kaplan–Meier method and compared by the log-rank test. For 
the Kaplan–Meier method, the intensities of global glomerulosclerosis/collapsing 
glomerulopathy and ischemic nephropathy were divided into three (0, lowest tertile; 1, 
middle tertile; and 2, highest tertile), and those for segmental glomerulosclerosis were 
divided into two (0, 0%; and 1, >0%). 
  All analyses were conducted using SPSS, version 19 (SPSS, Tokyo, Japan). A 
two-sided p value of <0.05 was considered statistically significant.
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RESULTS 
Clinical and pathological baseline characteristics for each CKD heat map category  
This study evaluated 600 patients with a mean observation period of 72.4 months. 
The baseline clinical characteristics of the patients at the time of kidney biopsy are 
shown in Table 2A. The mean age was 57.8 ± 11.6 (59, 51-66) years, and 67% of the 
patients were male. The mean systolic and diastolic BP were 144.5 ± 21.6 (142, 
130-160) and 78.9 ± 12.5 (80, 70-88) mmHg, respectively, and the mean HbA1c was 
7.6% ± 2.0% (7.1, 6.1-8.8) (mean 59 mmol/mol). There were statistically significant 
differences between the groups in gender, age, systolic and diastolic BP, Hb, HbA1c, 
and total cholesterol (Table 2A). Age, systolic and diastolic BP, and total cholesterol 
were found to be higher in the higher-risk CKD heat map categories, with statistically 
significant differences in these variables between the Green and Yellow group and the 
Red group. By contrast, Hb and HbA1c were found to be lower in the higher-risk 
categories; again, there was a statistically significant difference between the Green and 
Yellow group and the Red group. The rate of renin–angiotensin system inhibitor 
treatment was significantly lower in Green and Yellow group than in the other groups 
(Table 2A). 
The baseline pathological characteristics of the patients in this study are shown in 
Table 2B. Diffuse lesions were advanced and the mean severity score was 2.07 ± 0.98 
(2, 1-3). Very few nodular lesions and mesangiolysis cases were observed, and the 
scores for these were 0.42 ± 0.49 (0, 0-1) and 0.38 ± 0.49 (0, 0-1), respectively. Global 
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sclerosis and segmental sclerosis were observed in 24.29% ± 22.59% (20, 5-38) and 
3.76% ± 8.42% (0, 0-5) of glomeruli. Hyalinosis was widely observed in vascular 
lesions, with a mean severity score of 2.13 ± 1.00 (2, 1-3). 
All pathological findings differed significantly between the three groups (Table 2B). 
The pathological scores for glomerular, interstitial, and vascular lesions were found to 
be higher in the higher-risk categories, and were highest for the Red group. Scores 
differed significantly between the Green and Yellow group and the Red group. Each 
pathological finding correlated strongly with the scores for the other pathological 
findings. However, there was no difference in IgG deposition score between the groups 
(Green and Yellow, 1.5 ± 0.8; Orange, 1.4 ± 0.8; and Red, 1.2 ± 0.8). The incidences of 
composite kidney end points, dialysis, and all-cause mortality were significantly higher 
in the higher-risk categories. 
The composite kidney end point (dialysis, doubling of Cr, or halving of eGFR), CKD 
G5D (dialysis or kidney transplantation), cardiovascular events, and death were 
observed in 304, 31, 76, and 73 patients, respectively (Table 3A). The incidence of each 
outcome is presented as 100 person-years in Table 3B. The rates of composite kidney 
end point, dialysis, cardiovascular events, and all-cause mortality in the three groups 
were found to be higher in the higher-risk categories. The incidence rates per 100 
person-years for the Green and Yellow, Orange, and Red groups were as follows: 2.31, 
6.59, and 14.52 for the composite kidney end point; 0.36, 0.75, and 2.20 for CKD G5D; 
2.05, 2.15, and 3.21 for cardiovascular events; and 0.81, 1.35, and 3.44 for death (Table 
3B). 
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These findings were confirmed by the survival curves for each outcome derived using 
the Kaplan–Meier method and analyzed with the log-rank test (Figure 1). For the 
composite kidney end point, the survival curve for the Green and Yellow group was 
significantly better than that for the Orange and Red groups (Figure 1A). For CKD G5D 
and all-cause mortality, the survival curves of the Red group were significantly poorer 
than those of the other two groups (Figure 1B, D). However, there was little or no 
difference between the three groups in the curves for cardiovascular events (Figure 1C). 
 
Pathological findings were detected even in the green or yellow CKD heat map category 
cases  
 Pathological scores increased in accordance with increasing CKD heat map category 
(Table 4). However, diffuse lesions, polar vasculosis, and subendothelial space 
widening were commonly detected even in the Green and Yellow group (positive cases: 
diffuse lesions 81.6%, polar vasculosis 42.6%, and subendothelial space widening 
35.1%). 
 In contrast, around half of the Red group patients were negative for nodular lesions, 
exudative lesions, mesangiolysis, and glomerulomegaly (negative cases: nodular lesions 
46.4%, exudative lesions 40.4%, mesangiolysis 52.3%, and glomerulomegaly 59.7%). 
 
Pathological scores could clearly predict the occurrence of composite kidney events in 
each CKD heat map category, particularly in the low-risk green and yellow categories. 
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In addition to the CKD heat map category, all thirteen pathological measures could 
clearly predict the occurrence of composite kidney events (Supplementary Figure 2). 
Among the thirteen pathological measures, nodular lesions, exudative lesions, and 
mesangiolysis showed special effects on prediction of composite kidney events, 
especially in the low-risk green and yellow categories (Figure 2). 
The adjusted hazard ratios (HRs) of nodular lesions, exudative lesions, and 
mesangiolysis for the composite kidney event are shown in Table 5. Cox proportional 
hazards analysis revealed that these three pathological factors were positively associated 
with the composite kidney event in the Green and Yellow, Orange, and Red groups after 
adjustment for BMI, systolic BP, HbA1c, and T-cho. However, the HRs of the Green 
and Yellow group compared with the Orange and Red groups for the outcomes of 
nodular lesion, exudative lesion, and mesangiolysis were significantly high (HR, 95% 
confidence interval: nodular lesion 21.1, 5.3–84.6; exudative lesion 5.1, 1.3–20.3; 
mesangiolysis 7.6, 2.0–28.3). 
 Although the HR for the composite kidney events of nodular lesion, exudative 
lesion, and mesangiolysis were significantly high in the Green and Yellow group, the 
baseline data for the clinical factors showed almost no difference between positive and 
negative cases of nodular lesion, exudative lesion, and mesangiolysis (Table 6).  
IgG deposition and renin–angiotensin system inhibitor treatment at kidney biopsy did 
not show any significant differences for each outcome (data not shown).   
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DISCUSSION 
In this cohort study of biopsy-confirmed diabetic nephropathy cases, we found that 
the CKD heat map category is a good predictor for composite kidney events, CKD G5D, 
and all-cause mortality. We also demonstrated the value of pathological evaluation for 
predicting the prognosis in diabetic kidney disease. Certain pathological findings 
(nodular lesions, exudative lesions, and mesangiolysis) were useful predictive factors 
for composite kidney events, particularly in patients in the low (green or yellow) CKD 
heat map categories. Furthermore, our study demonstrated that even in these categories, 
diffuse lesions, polar vasculosis, and subendothelial space widening were common. 
These findings indicate that pathological characteristics provide useful information for 
predicting the prognosis of diabetic kidney disease, especially in cases of low-risk CKD 
heat map categories.  
Our results demonstrated that pathological findings of nodular lesions, exudative 
lesions, and mesangiolysis add predictive information for composite kidney events, 
particularly for patients in the low-risk green and yellow CKD heat map categories. It 
has been well established that raised albuminuria is a risk for the progression of kidney 
dysfunction [7]. Our data also indicated that in cases with advanced albuminuria and 
decreased eGFR, albuminuria and eGFR were good predictors for kidney dysfunction, 
cardiovascular events, and all-cause mortality. Although all our pathological scores 
were statistically significant for the prediction of kidney events in all cases, these 
pathological findings added negligible predictive information for the outcomes in the 
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higher-risk orange and red categories. In contrast, the green and yellow category 
patients with nodular lesions, exudative lesions, and mesangiolysis showed remarkably 
poorer outcomes with regard to composite kidney events than did the cases with the 
particular pathological findings. Nodular lesions and mesangiolysis were characteristic 
pathological findings for DN and have been reported as predictive markers for improper 
renal function [7, 8]. Exudative lesion is also a typical pathological change in DN. A 
previous study indicated that patients without exudative lesions had a significantly 
better renal survival rate than those with such lesions [10]. It is important to perform a 
renal biopsy for patients with type 2 diabetes and to limit clinical changes for two 
reasons: to exclude non-diabetic renal diseases, which may benefit from specific 
treatment [16]; and second, to define the risk worse renal outcomes (end-stage kidney 
disease) developing and guide therapeutic management [17]. In this study, we indicated 
that the effects were more significant in the low-risk CKD heat map categories, and 
emphasize the importance of these pathological findings for predicting kidney 
dysfunction, particularly in cases with normoalbuminuria to microalbuminuria and 
preserved kidney function.  
The progression of diabetic kidney disease is heterogeneous [5]. A previous study 
showed that, despite most cases of diabetes with normoalbuminuric and 
microalbuminuric remaining stable for a long period, some cases with microalbuminuria 
showed a rapid decline in glomerular filtration rate [18]. However, to date no good 
biomarker or clinical finding exists for predicting the progression of diabetic kidney 
disease in patients with low-grade albuminuria and preserved eGFR. Our study has 
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identified pathological findings that add important predictive information about the 
progression of kidney disease, particularly in patients in the low-risk CKD heat map 
categories. Urinary or serum biomarkers that correlate well with pathological changes 
may provide clear indication of when kidney biopsy is required for diabetic patients. 
Such biomarkers should be considered in future studies. 
The present study demonstrated that, even in low-risk categories with normal kidney 
function and normo- to microalbuminuria, particular pathological findings (diffuse 
lesions, polar vasculosis, and subendothelial space widening) were commonly detected. 
The report by Fioretto et al. as well as other recent histological studies indicates that 
heterogeneity is present at an early stage in diabetic nephropathy [4, 19, 20]. 
Furthermore, some of these pathological changes were not specific to DN. Recent basic 
studies have indicated the importance of glomerular endothelial injury in various kidney 
diseases, including DN [9, 21-23]. Widening of the subendothelial space could be a 
phenotype of endothelial injury. Further studies are needed to evaluate the sensitivity 
and specificity of these pathological findings for DN. 
Tubulointerstitial lesions, vascular lesions, and global glomerulosclerosis are also 
observed in cases of hypertension, smoking, or obesity, or with advanced age [22]. 
These additional clinical factors could affect the pathological findings in diabetic 
patients. Therefore, additional studies are required with larger numbers of patients with 
early-stage diabetic kidney disease. We should also try to detect the pathological 
changes of diabetic kidney disease before albuminuria or a decline in eGFR through 
biopsy or by using new biomarkers.  
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  This study had several limitations. First, we only evaluated pathological findings by 
light microscopy. Further evaluation with electron microscopy should be performed in 
future studies. Furthermore, the reproducibility of scoring for each pathological finding 
is an important point, and future studies will be required to establish this. Second, this 
was a retrospective study. The collected laboratory data and outcomes depended on 
clinical records. Third, biopsy procedures and biopsy sample handling processes were 
not uniform across the 13 centers. Fourth, subjects were limited to patients who had 
undergone a kidney biopsy. As a kidney biopsy was only performed when clinically 
relevant, such as in patients with hematuria or acute kidney injury, these factors may 
have affected our results. Before generalizing this result to all diabetic cases, the 
possibility of selection bias from biopsy policy or indication should be considered, and 
the findings of this study should be confirmed in other cohorts. Additionally, an 
indication bias for kidney biopsy could potentially explain the limited differences in 
cardiovascular events between the groups. Fifth, we did not evaluate the therapeutic 
interventions during follow-up; these may have impacted kidney prognosis. Although 
the rate of renin–angiotensin system inhibitor treatment was lowest in the Green and 
Yellow group, the incidence of the composite kidney end point in this group was lower 
than in the other groups. Furthermore, renin–angiotensin system inhibitor treatment did 
not prevent survival curve at kidney biopsy for each outcome. Finally, the data for 
proteinuria were used when data for albuminuria were not available. A comparison 
between our classification system and that of Tervaert et al. will be our next project. 
Although these limitations may have affected the interpretation of our results to some 
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extent, this multicenter study involving 600 kidney biopsy samples with long-term 
follow-up clinical data is important for understanding the clinicopathological features of 
diabetic kidney lesions and clinical outcomes. 
 In conclusion, among the various clinical and pathological parameters, the presence 
of subendothelial space widening, advanced interstitial cell infiltration, segmental 
sclerosis, and glomerulomegaly are predictors for renal and cardiovascular events in 
type 2 diabetic patients with preserved eGFR and normoalbuminuria to 
microalbuminuria. These results clearly suggest that pathological characteristics provide 
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Figure 1. Kaplan–Meier survival curves for each outcome.  
Survival curves for: (A) composite kidney end points, (B) CKD G5D, (C) 
cardiovascular events, and (D) all-cause mortality. Classification into CKD heat map 
categories (Green and Yellow [G & Y], Orange, and Red) is shown for all end points. 
Differences between the groups were compared using the log-rank test. 
 
Figure 2.  Kaplan–Meier survival curves for composite kidney end points stratified 
by each pathological score.  
Event-free curves for the composite kidney end points are shown. Each column 
shows the event-free curves for all cases and for the Green and Yellow (G & Y), Orange, 
and Red groups. Each row shows the pathological findings (nodular lesion, exudative 
lesion, and mesangiolysis [MesLy]), and each line indicates the score. The continuous 
black line indicates score 0, and the blue line indicates score 1. Differences between 
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SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary Figure 1 
 
Definition of pathological findings  
Diffuse lesion (mesangial expansion) 
  A diffuse lesion is defined as mesangial matrix expansion that is double the width of 
the nucleus of a mesangial cell. The lesion should be detected in at least two peripheral 
lobules in one glomerulus.  
Nodular lesion (nodular sclerosis) 
 A nodular lesion is defined as a rounded mesangial matrix expansion where no normal 
capillary is present.   
Supportive findings: A typical nodular lesion exhibits low PAM and Periodic Acid–
Schiff (PAS) staining. Uptake with PAM and PAS should be standardized by arterial 
media. A low PAM and PAS staining area is usually blue with Masson’s trichrome 
staining. The difference between diffuse and nodular lesions is the presence of normal 
capillaries around a diffuse lesion and the absence of normal capillaries around a 
nodular lesion. 
Subendothelial space widening 
 Edematous widening of the subendothelial space indicated subendothelial space 
widening. 
Exudative lesion 
 An exudative lesion is defined by serum amorphous protein deposits in the 
subendothelial space (fibrin cap) or Bowman’s capsule wall (capsular drop). 
Mesangiolysis/microaneurysm 
 Mesangiolysis is defined as dissolution or attenuation of the mesangial matrix and 
degeneration of mesangial cells. 
Peri-hilar neovascularization 
 There is neovascularization in the glomerular hilar region around the afferent and 
efferent arterioles, and the vascular wall often has hyalinosis. 
Global glomerulosclerosis, collapsing glomerulopathy, and ischemic nephropathy 
 All the glomerulocapillaries are sclerosed, the capillary lumen is not detected, and the 
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glomerulocapillaries are collapsing. 
Segmental glomerulosclerosis 
 In segmental glomerulosclerosis, part of the glomerulocapillaries is sclerosed. 
Glomerulomegaly 
 In glomerulomegaly, one or more glomerular diameter is greater than 250 μm in all 
biopsy specimens. In 400× visual field microscopy, the glomerular diameter is usually 
around 500 μm. 
Interstitial fibrosis, IFTA 
 Interstitial fibrosis is defined as the accumulation of collagen and related molecules in 
the interstitium. Tubular atrophy is defined as a decrease in tubular diameter and 
number. 
Arteriolar hyalinosis 
 This is the ratio of hyaline thickness to whole arteriolar wall thickness expressed as a 
percentage. A totally occluded artery and an artery connecting to a globally sclerotic 
glomerulus are shown for comparison. 
Intimal thickening 
 Fibrous intimal thickening of an arteriole or larger artery (interlobular artery arcuate 
artery) should be evaluated together with the symmetrical wall. Advanced intimal 
thickening is dominant in some patients and the media is hard to detect. The branching 
artery is not evaluated.  
 
REFERENCE for SUPPLEMENTARY METHODS 
Wada T, Yuzawa Y (Eds.) (2014). Manual for pathological diagnosis of diabetic 
nephropathy and hypertensive nephrosclerosis. Tokyo Igakusha 
 
 
Supplementary Figure 2 
Kaplan–Meier survival curves for composite kidney end points stratified by each 
pathological score.  
Event-free curves for composite kidney end points are shown. Each column shows 
the event-free curves for all cases, the Green and Yellow group (G & Y), the Orange 
group, and the Red group. Each row shows all the pathological findings (including 
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nodular lesion, exudative lesion, and mesangiolysis, as shown in Figure 2), and each 
line indicates the score. The continuous black line indicates score 0, the blue line 
indicates score 1, the red line indicates score 2, and the purple line indicates score 3. 





Definition of pathologic findings 










Diffuse lesion (mesangial 
expansion) 
0-3 
0 normal or mild mesangial expansion， 
1 mesangial expansion≦capillary lumen， 
2 mesangial expansion=capillary lumen， 
3 mesangial expansion≧capillary lumen 
Nodular lesion （nodular 
sclerosis） 
0, 1 
0 (no nodular lesion）, 
1 (one or more lesions detected in all biopsy specimens , not care of 
nodular size） 
subendothelial space widening 
(double contour of basement 
membrane)  
0-3  
Double contour basement membrane (%)（Determined in peripheral 
capillary of the most severe glomerulus ）； 
0(＜10％)，1(10-25％)，2(25-50％)，3（≧50％） 
Exudative lesion 0, 1 
0 (not detected）, 
1 (detected one or more lesion in all biopsy specimen) 
Mesangiolysis/microaneurysm 0, 1 
0 (not detected）,  




0 (not detected）,  




glomerulopathy ・ ischemic 
nephropathy 
% 
(number of global glomerulosclerosis and collapsing 
glomerulopathy ・ ischemic nephropathy)/number of all glomerulus 
(%) 
Segmental glomerulosclerosis % 
number of segmental glomerulosclerosis/number of all glomerulus 
(%) 
Glomerulomegaly 0, 1 
glomeruli >250 μm in diameter    




Interstitial fibrosis and tubular 
atorophy (IFTA) 
0-3 0 (no IFTA), 1 (<25%), 2 (25-50%), 3 (≧50%) 




Arteriolar hyalinosis 0-3 
0 (no hyalinosis),  
1 (one or more partial arteriolar hyalinosis),  
2 (approximately  50％ hyalinosis),  
3 (more than 50％ hyalinosis，or penetrating hyalinosis） 
Intimal thickening 0-2 
0 (no intimal thickening),  
1 (intimal thickness/media thickness＜１),  
2 (intimal thickening and intimal thickness/media thickness≧１) ＥＶ
Ｇ staining is helpful for determination 
 
Table 2 
A  Clinical baseline characteristics of this study 












 (% of male) 
53 60 73 #, § 67 <0.01 
Age 
































































Tcho 196.1±48.6  218.7±57.2 # 222.6±81.1 # 217.3±71.9  <0.01 
 (mg/dL) (195, 163-229) (212, 182-241) (207, 172-249) (207, 174.5-243) 
RAS 
 (%) 
11.5 56.1 #        65.5 #       58.3 <0.01 
B.  Pathological baseline characteristics of this study 
 
 
    G & D Orange Red All ANOVA 















1.99±0.96 #  
(2, 1-3) 








0.32±0.47 #  
(0, 0-1) 








0.76±0.89 #  
(1, 0-1) 








0.36±0.48 #  
(0, 0-1) 








0.32±0.47 #  
(0, 0-1) 








0.67±0.47 #  
(1, 0-1) 








































1.42±0.89 #  
(1, 1-2) 








1.05±0.78 #  
(1, 1-1) 










2.05±1.01 #  
(2, 1-3) 








1.09±0.77 #  
(1, 1-2) 







BMI; body mass index, sysBP; systolic blood pressure, diaBP; diastolic blood pressure, Hb; hemoglobin, Tcho; total cholesterol, 
RAS; rate of renin angiotensin system inhibitor treatment, IQR; interquartile range 
Diffuse; diffuse lesion (mesangial expansion), Nodular; nodular lesion (nodular sclerosis), SubendW; subendothelial space 
widening (double contour of basement membrane), Exudative; exudative lesion, MesLy; mesangiolysis/microaneurysm, PVas 
peri-hilar neo-vascularization (polar vasculosis), GScl; global glomerulosclerosis/collapsing glomerular change · ischemic 
glomerular change, SScl; segmental glomerulosclerosis, GMeg; glomerulomegaly; IFTA; interstitial fibrosis and tubular 
atrpophy, ICell; interstitial cell infiltration, Hyalin; arteriolar hyalinosis, Arterio, Arteriosclerosis with intimal thickening   
P was calculated by one way ANOVA test. # indicates statistical significance compared with G & Y, and § with Orange by paired 
t test. 
  
Table 3  The incidence rates of composite kidney end points and kidney death were increased accompanied with increase of 
proteinuria or decrease of eGFR.  
 
A. Actual number of events in each category.  
 
    G & Y Orange Red All 
Composite 
kidney event 
Event - 72 73 120 265 
Event + 20 68 216 304 
          
     G & Y Orange Red All 
Kidney death 
Event - 58 103 231 392 
Event + 2 5 24 31 
          
     G & Y Orange Red All 
CV event 
Event - 62 96 239 397 
Event + 16 20 40 76 
          
     G & Y Orange Red All 
All cause Event - 86 129 285 500 
mortality Event + 7 14 52 73 
 
B. Incidence rates of each outcome (/100 person-years) 
 
 
G & Y Orange Red All 
Composite kidney event 2.31  6.59  14.52  8.97  
Kidney death 0.36  0.75  2.20  1.34  
CV event 2.05  2.15  3.21  2.57  
All cause mortality 0.81  1.35  3.44  2.13  
 
CV event; cardiovascular event 




Table 4.  The percent of each histological score in clinical stage  
 
Diffuse     MesLy     ICell 
Score G & Y Orange Red Total 
 
Score G & Y Orange Red Total 
 
Score G & Y Orange Red Total 
0 18.4 6.0 3.9 7.0 
 
0 87.4 68.0 52.3 62.5 
 
0 40.8 20.8 5.9 15.7 
1 46.6 28.2 14.3 23.5 
 
1 12.6 32.0 47.7 37.5 
 
1 44.7 59.7 51.3 52.3 
2 23.3 26.8 25.0 25.2 
  
100.0 100.0 100.0 100.0 
 
2 13.6 12.8 27.0 21.1 
3 11.7 38.9 56.8 44.4 
 
PVas 
     
3 1.0 6.7 15.8 11.0 
 
100.0 100.0 100.0 100.0 
 
Score G & Y Orange Red Total 
  
100.0 100.0 100.0 100.0 
Nodular 
     
0 57.4 33.3 23.4 31.8 
 
Hyalin 
    Score G & Y Orange Red Total 
 
1 42.6 66.7 76.6 68.2 
 
Score G & Y Orange Red Total 
0 84.2 67.6 46.4 58.3 
  
100.0 100.0 100.0 100.0 
 
0 24.3 6.8 3.3 7.8 
1 15.8 32.4 53.6 41.7 
 
GMeg 
     
1 30.1 27.7 15.4 21.1 
 
100.0 100.0 100.0 100.0 
 
Score G & Y Orange Red Total 
 
2 17.5 19.6 23.1 21.3 
SubendW  
    
0 78.0 69.4 59.7 65.3 
 
3 28.2 45.9 58.2 49.8 
Score G & Y Orange Red Total 
 
1 22.0 30.6 40.3 34.7 
  
100.0 100.0 100.0 100.0 
0 64.9 48.6 23.8 37.2 
  
100.0 100.0 100.0 100.0 
 
Arterio 
    1 25.8 32.6 40.4 35.9 
 
IFTA 
     
Score G & Y Orange Red Total 
2 4.1 13.2 21.0 16.1 
 
Score G & Y Orange Red Total 
 
0 36.8 23.4 8.3 16.9 
3 5.2 5.6 14.8 10.8 
 
0 35.9 13.4 2.3 10.9 
 
1 38.9 46.8 46.9 45.6 
 
100.0 100.0 100.0 100.0 
 
1 42.7 44.3 20.5 30.3 
 
2 24.2 27.7 42.9 35.9 
Exudative 
     
2 18.4 28.9 35.4 30.8 
 
3 0.0 2.1 1.8 1.6 
Score G & Y Orange Red Total 
 
3 2.9 13.4 41.8 27.9 
  
100.0 100.0 100.0 100.0 
0 84.5 64.4 40.4 54.2 
  
100.0 100.0 100.0 100.0 
      1 15.5 35.6 59.6 45.8 
            
 
100.0 100.0 100.0 100.0 









Diffuse; diffuse lesion (mesangial expansion), Nodular; nodular lesion (nodular sclerosis), SubendW; subendothelial space 
widening (double contour of basement membrane), Exudative; exudative lesion, MesLy; mesangiolysis/microaneurysm, PVas 
peri-hilar neo-vascularization (polar vasculosis), GMeg; glomerulomegaly; IFTA; interstitial fibrosis and tubular atrpophy, 
ICell; interstitial cell infiltration, Hyalin; arteriolar hyalinosis, Arterio, Arteriosclerosis with intimal thickening   
  
Table 5   HRs of nodular lesion, exudative lesion and mesangiolysis for the composite kidney events 
 Univariate     Model 1     Model 2 
Nodular 
 
  HR 95% CI     p   
  HR 95% CI     p   
  HR 95% CI     p 
All Score 0 Reference    
All Score 0 Reference    
All Score 0 Reference   
 
Score 1 2.4 ( 1.9 - 3.1 ) <0.01   
Score 1 2.4  ( 1.9  - 3.1 ) <0.01   
Score 1 2.2  ( 1.7  - 2.9 ) <0.01 
G & Y Score 0 Reference    
G & Y Score 0 Reference    
G & Y Score 0 Reference   
 
Score 1 10.2 ( 3.6 - 28.6 ) <0.01   
Score 1 12.9 ( 3.9  - 43.1 ) <0.01   
Score 1 21.1 ( 5.3  - 84.6 ) <0.01 
Orange Score 0 Reference    
Orange Score 0 Reference    
Orange Score 0 Reference   
 
Score 1 1.7 ( 1 - 2.8 ) <0.05   
Score 1 1.7 ( 1.0  - 2.8 ) <0.05   
Score 1 1.2 ( 0.6  - 2.2 ) 0.64  
Red Score 0 Reference    
Red Score 0 Reference    
Red Score 0 Reference   
 
Score 1 1.7 ( 1.3 - 2.3 ) <0.01   
Score 1 1.7 ( 1.3  - 2.3 ) <0.01   
Score 1 1.7 ( 1.2  - 2.3 ) <0.01 
              
              Exudative 
             
 
  HR 95% CI     p   
  HR 95% CI     p   
  HR 95% CI     p 
All Score 0 Reference    
All Score 0 Reference    
All Score 0 Reference   
 
Score 1 2.8 ( 2.2 - 3.6 ) <0.01   
Score 1 2.8  ( 2.2  - 3.6 ) <0.01   
Score 1 2.6  ( 2.0  - 3.5 ) <0.01 
G & Y Score 0 Reference    
G & Y Score 0 Reference    
G & Y Score 0 Reference   
 
Score 1 4.3 ( 1.5 - 12.1 ) <0.01   
Score 1 4.2 ( 1.4  - 12.9 ) <0.01   
Score 1 5.1 ( 1.3  - 20.3) <0.05 
Orange Score 0 Reference    
Orange Score 0 Reference    
Orange Score 0 Reference   
 
Score 1 2.1 ( 1.3 - 3.5 ) <0.01   
Score 1 2.1 ( 1.3  - 3.5 ) <0.01   
Score 1 1.7 ( 0.9  - 3.3 ) 0.10  
Red Score 0 Reference    
Red Score 0 Reference    
Red Score 0 Reference   
 
Score 1 1.9 ( 1.4 - 2.5 ) <0.01   
Score 1 1.9 ( 1.4  - 2.5 ) <0.01   
Score 1 1.8 ( 1.2  - 2.5 ) <0.01 
              
              MesLy 
             
 
  HR 95% CI     p   
  HR 95% CI     p   
  HR 95% CI     p 
All Score 0 Reference    
All Score 0 Reference    
All Score 0 Reference   
 
Score 1 2.7 ( 2.1 - 3.4 ) <0.01   
Score 1 2.7  ( 2.1  - 3.4 ) <0.01   
Score 1 2.4  ( 1.8  - 3.2 ) <0.01 
G & Y Score 0 Reference    
G & Y Score 0 Reference    
G & Y Score 0 Reference   
 
Score 1 5.6 ( 1.9 - 16.8 ) <0.01   
Score 1 5.4 ( 1.7  - 17.4 ) <0.01   
Score 1 7.6 ( 2.0  - 28.8 ) <0.01 
Orange Score 0 Reference    
Orange Score 0 Reference    
Orange Score 0 Reference   
 
Score 1 1.9 ( 1.1 - 3.1 ) <0.05   
Score 1 1.8 ( 1.1  - 3.1 ) <0.05   
Score 1 1.4 ( 0.7  - 2.8 ) 0.31  
Red Score 0 Reference    
Red Score 0 Reference    
Red Score 0 Reference   
 
Score 1 1.9 ( 1.5 - 2.6 ) <0.01   
Score 1 1.9 ( 1.5  - 2.6 ) <0.01   
Score 1 1.8 ( 1.3  - 2.6 ) <0.01 
 
Nodular; nodular lesion (nodular sclerosis), Exudative; exudative lesion, MesLy; mesangiolysis/microaneurysm 
Model 1: Adjusted for age, gender. Model 2: Adjusted for the covariates in model 1, body mass index, systolic blood pressure, 


































20.9±6.6   
(21.8,19.8-24.5 ) 
134.9±21.5   
(140,120-148) 
75.4±9.4   
(78,70-80) 
13.0±2.0   
(13.0,12.0-14.7) 
8.3±1.9   
(8.1,7.4-8.9) 
201.4±64.0   
(190,155-241) 








23.6±5.1   
(22.7,20.8-25.4 ) 
130.5±20.3   
(129,118-140) 
75.7±12.4   
(78,70-84) 
13.6±1.7   
(13.6,12.6-14.9) 
8.4±2.4   
(8,6.5.0-10.4) 
195.4±45.7   
(196,165-229) 




p 0.12 0.44 0.08 0.48 0.92 0.22 0.95 0.67 0.13 0.06 
           
Exudative Age Gender BMI SysBP DiaBP Hb HbA1c Tcho eGFR UAlb 
+ 
57.9±9.7   
(57,52-65) 
62  
20.4±6.7   
(21.2,19.5-23.4 ) 
129.7±20.0   
(132,112-140) 
72.9±7.8   
(72,70-80) 
13.0±1.9   
(12.8.0,12.0-14.0) 
8.5±2.1   
(8.0,7.2-9.0) 
197.1±61.0   
(188,155-220) 
68.5±14.1   
(66.1,60.8-74.4 ) 












13.6±1.7   
(13.7,12.7-15.0) 






0.06±0.08   
(0.03,0-0.12) 
p 0.19 0.44 <0.05 # 0.76 0.33 0.21 0.83 0.93 <0.05 # 0.25 
           
MesLysis Age Gender BMI SysBP DiaBP Hb HbA1c Tcho eGFR UAlb 
+ 
59.7±8.6   
(57,52-65) 
69  
23.0±4.1   
(22.0,19.7-25.8 ) 
136.9±19.7   
(140,132-148) 




8.1±0.9   
(8,7.5-8.8) 
197.8±64.7   
(189,159-211.5) 
71.2±13.6   
(66.5,61.2-79.7 ) 
















195.8±46.1   
(195,164-232) 




p 0.08 0.22 0.88 0.32 0.92 0.17 0.47 0.89 0.07 0.23 
 
  
Nodular; nodular lesion (nodular sclerosis), Exudative; exudative lesion, MesLy; mesangiolysis/microaneurysm 
BMI; body mass index, sysBP; systolic blood pressure, diaBP; diastolic blood pressure, Hb; hemoglobin, Tcho; total choresterol, 
RAS; rate of renin angiotensin system inhibitor treatment, IQR; interquartile range 
# indicates statistical significance by paired t test. 
Supplementary Table 1   








0 normal or mild mesangiumu expansion， 
1 mesangiumu expansion≦capimally lumen,  
2 mesangiumu expansion=capimally lume,  






Nodular (Class III) 
↓ 
Mesangial expansion>50% 
(Diffuse) (Class IIB, IIA) 
↓ 
Glomerular basement membrane 
thickening by electron microscopy 
(Class I) 
Nodular 
0 (no nodular lesion）, 1(one or more nodular lesion in 
all biopsy specimen, not care of nodular size）  
SubendW 
double contour of basement membrane (%)； 
0(＜10％)，1(10-25％)，2(25-50％)，3（≧50％）  
Exudative 
0 (not detected),  
1 (detected one or more lesion in all biopsy specimen)  
MesLy 
0 (not detected),  
1 (detected one or more lesion in all biopsy specimen)  
PVas 
0 (not detected),  
1 (detected one or more lesion in all biopsy specimen)  
GScl 
(number of global glomerulosclerosis and collapsing 
glomerulopathy ・ ischemic nephropathy)/number of 
all glomerulus (%)  
SScl 
number of segmental glomerulosclerosis/number of 
all glomerulus (%)  
GMeg 
more than 250μm in glomerular diameter   
0 (not detected）, 1 (detected)  
Interstitial 
lesions 
IFTA 0 (no IFTA), 1 (<25%), 2 (25-50%), 3 (≧50%)  
0 (no IFTA), 1 (<25%), 2 (25-50%),  
3 (≧50%) 
ICell 
0 (no cell infiltration), 1 (<25%), 2 (25-50%),  
3 (≧50%)  
0 (no infiltration), 1(infiltration only in 





0 (no hyalinosis),  
1 (one or more partial arterioral hyalinosis),  
2 (around 50％ hyalinosis),  
3 (more than 50 ％  hyalinosis ， or penetrating 
hyalinosis) 
 
0 (no hyalinosis),  
1 (at least one area of arteriolar 
hyalinosis),  
2 (more than one area of arteriolar 
hyalinosis) 
Arterio 
0 (no intimal thickning),  
1 (intimal thickness/media thickness＜１),  
2 (intimal thickning and intimal thickness/media 
thickness≧ １ ) EVG staining is helpful for 
determination 
 
Intimal thickening greater than thickness 
of media 
Diffuse; diffuse lesion (mesangial expansion), Nodular; nodular lesion (nodular sclerosis), SubendW; subendothelial space 
widening (double contour of basement membrane), Exudative; exudative lesion, MesLy; mesangiolysis/microaneurysm, PVas 
peri-hilar neo-vascularization (polar vasculosis), GScl; global glomerulosclerosis/collapsing glomerular change · ischemic 
glomerular change, SScl; segmental glomerulosclerosis, GMeg; glomerulomegaly; IFTA; interstitial fibrosis and tubular 
atrpophy, ICell; interstitial cell infiltration, Hyalin; arteriolar hyalinosis, Arterio, Arteriosclerosis with intimal thickening  




Supplementary Table 2 
Biopsy indication (single center survey of 50 case series with normo- or micro-albuminuria) 
 Cause of biopsy Number of cases 
Normo-albuminuria  31 cases (62%) 
 Decreased eGFR 19 cases (38%) 
Micro-albuminuria  17 cases (34%) 
 Decreased eGFR 10 cases (20%) 
 No diabetic retinopathy 8 cases (16%) 
 Short duration of diabetic history 6 cases (12%) 
 Highly speculated other diesases 2 cases (4%) 
58% was cases of rapid decline in eGFR, 16% was cases with proteinuria without diabetic retinopathy, and 12% was cases of 
proteinuria with short duration of diabetic history 
  
Supplementary Table 3 
  HRs of nodular lesion, exudative lesion and mesangiolysis for the cardiovascular events 
 
 Univariate           Model 1    Model 2 
Nodular 
    HR 95% CI     p       HR 95% CI     p       HR 95% CI     p 
All Score 0 Reference 
 
  All Score 0 Reference 
 
  All Score 0 Reference 
 
 
Score 1 1.6(0.9-2.8) 0.102   
 
Score 1 1.4(0.8-2.6) 0.228   
 
Score 1 1.4(0.7-2.6) 0.310 
G & Y Score 0 Reference 
 
  G & Y Score 0 Reference 
 
  G & Y Score 0 Reference 
 
 
Score 1 2.6(0.5-12.6) 0.242   
 
Score 1 2.2(0.4-12.6) 0.382   
 
Score 1 3.2(0.3-30.2) 0.319 
Orange Score 0 Reference 
 
  Orange Score 0 Reference 
 
  Orange Score 0 Reference 
 
 
Score 1 1.4(0.5-3.8) 0.515   
 
Score 1 1.2(0.4-3.2) 0.773   
 
Score 1 1.3(0.4-3.8) 0.617 
Red Score 0 Reference 
 
  Red Score 0 Reference 
 
  Red Score 0 Reference 
 
 
Score 1 1.5(0.6-3.4) 0.372   
 
Score 1 1.4(0.6-3.3) 0.404   
 






    
  
    
   HR 95% CI     p       HR 95% CI     p       HR 95% CI     p 
All Score 0 Reference 
 
  All Score 0 Reference 
 
  All Score 0 Reference 
 
 
Score 1 1.6(0.9-2.8) 0.120   
 
Score 1 1.5(0.9-2.7) 0.147   
 
Score 1 1.4(0.8-2.7) 0.277 
G & Y Score 0 Reference 
 
  G & Y Score 0 Reference 
 
  G & Y Score 0 Reference 
 
 








Score 1 NA 
 
Orange Score 0 Reference 
 
  Orange Score 0 Reference 
 
  Orange Score 0 Reference 
 
 
Score 1 1.2(0.4-3.3) 0.709   
 
Score 1 1.2(0.5-3.4) 0.667   
 
Score 1 1.1(0.4-3.6) 0.839 
Red Score 0 Reference 
 
  Red Score 0 Reference 
 
  Red Score 0 Reference 
 
 
Score 1 1.9(0.8-4.5) 0.141   
 
Score 1 2.0(0.8-4.7) 0.124   
 
Score 1 2.6(0.9-7.5) 0.079 
 
MesLy    
  
    
  
    
    HR 95% CI     p       HR 95% CI     p       HR 95% CI     p 
All Score 0 Reference 
 
  All Score 0 Reference 
 
  All Score 0 Reference 
 
 
Score 1 1.4(0.8-2.7) 0.246   
 
Score 1 1.5(0.8-2.8) 0.219   
 
Score 1 1.3(0.7-2.7) 0.427 
G & Y Score 0 Reference 
 
  G & Y Score 0 Reference 
 
  G & Y Score 0 Reference 
 
 
Score 1 2.2(0.3-18.0) 0.470   
 
Score 1 2.0(0.2-17.1) 0.543   
 
Score 1 3.9(0.4-42.7) 0.263 
Orange Score 0 Reference 
 
  Orange Score 0 Reference 
 
  Orange Score 0 Reference 
 
 
Score 1 1.8(0.7-4.8) 0.222   
 
Score 1 1.9(0.7-5.2) 0.183   
 
Score 1 2.4(0.8-7.6) 0.135 
Red Score 0 Reference 
 
  Red Score 0 Reference 
 
  Red Score 0 Reference 
 
 
Score 1 0.9(0.4-2.3) 0.821   
 
Score 1 0.9(0.4-2.3) 0.844   
 
Score 1 0.7(0.2-2.3) 0.533 
 
Nodular; nodular lesion (nodular sclerosis), Exudative; exudative lesion, MesLy; mesangiolysis/microaneurysm 
Model 1: Adjusted for age, gender. Model 2: Adjusted for the covariates in model 1, body mass index, systolic blood pressure, 
HbA1c, total cholesterol. 
  
Supplementary Table 4 
   HRs of nodular lesion, exudative lesion and mesangiolysis for the all cause mortality 
 
 Univariate    Model 1     Model 2 
Nodular 
    HR 95% CI     p       HR 95% CI     p       HR 95% CI     p 
All Score 0 Reference 
 
  All Score 0 Reference 
 
  All Score 0 Reference 
 
 
Score 1 2.4(1.5-3.9) <0.01   
 
Score 1 2.1(1.3-3.4) <0.01   
 
Score 1 1.8(1.0-3.1) <0.05 
G & Y Score 0 Reference 
 
  G & Y Score 0 Reference 
 
  G & Y Score 0 Reference 
 
 
Score 1 3.9(0.7-22.3) 0.127   
 
Score 1 1.7(0.2-12.6) 0.586   
 
Score 1 1.0(0.1-10.6) 0.979 
Orange Score 0 Reference 
 
  Orange Score 0 Reference 
 
  Orange Score 0 Reference 
 
 
Score 1 2.8(1.0-8.1) 0.054   
 
Score 1 2.3(0.8-6.8) 0.130   
 
Score 1 0.9(0.8-10.6) 0.103 
Red Score 0 Reference 
 
  Red Score 0 Reference 
 
  Red Score 0 Reference 
 
 
Score 1 1.5(0.8-2.7) 0.173   
 
Score 1 1.6(0.9-2.9) 0.142   
 






    
  
    
   HR 95% CI     p       HR 95% CI     p       HR 95% CI     p 
All Score 0 Reference 
 
  All Score 0 Reference 
 
  All Score 0 Reference 
 
 
Score 1 2.1(1.3-3.4) <0.01   
 
Score 1 2.0(1.2-3.2) <0.01   
 
Score 1 2.0(1.2-3.5) <0.05 
G & Y Score 0 Reference 
 
  G & Y Score 0 Reference 
 
  G & Y Score 0 Reference 
 
 
Score 1 1.9(0.2-16.4) 0.542   
 
Score 1 1.4(0.1-12.6) 0.782   
 
Score 1 2.3(0.1-42.6) 0.569 
Orange Score 0 Reference 
 
  Orange Score 0 Reference 
 
  Orange Score 0 Reference 
 
 
Score 1 1.7(0.6-5.0) 0.312   
 
Score 1 2.2(0.7-6.4) 0.163   
 
Score 1 1.6(0.4-6.1) 0.510 
Red Score 0 Reference 
 
  Red Score 0 Reference 
 
  Red Score 0 Reference 
 
 
Score 1 1.4(0.8-2.4) 0.304   
 
Score 1 1.4(0.8-2.6) 0.222   
 
Score 1 1.8(0.9-3.5) 0.101 
 
MesLy    
  
    
  
    
    HR 95% CI     p       HR 95% CI     p       HR 95% CI     p 
All Score 0 Reference 
 
  All Score 0 Reference 
 
  All Score 0 Reference 
 
 
Score 1 2.3(1.4-3.7) <0.01   
 
Score 1 2.9(1.7-4.8) <0.01   
 
Score 1 2.3(1.3-4.2) <0.01 
G & Y Score 0 Reference 
 
  G & Y Score 0 Reference 
 
  G & Y Score 0 Reference 
 
 
Score 1 2.4(0.3-22.1) 0.439   
 
Score 1 2.1(0.2-20.7) 0.520   
 
Score 1 3.5(0.2-66.3) 0.398 
Orange Score 0 Reference 
 
  Orange Score 0 Reference 
 
  Orange Score 0 Reference 
 
 
Score 1 2.4(0.8-7.1) 0.119   
 
Score 1 4.3(1.2-15.8) 0.025   
 
Score 1 3.2(0.8-13.4) 0.114 
Red Score 0 Reference 
 
  Red Score 0 Reference 
 
  Red Score 0 Reference 
 
 
Score 1 1.6(0.9-2.9) 0.123   
 
Score 1 2.2(1.2-4.1) 0.015   
 
Score 1 2.0(1.0-4.2) 0.054 
 
Nodular; nodular lesion (nodular sclerosis), Exudative; exudative lesion, MesLy; mesangiolysis/microaneurysm 
Model 1: Adjusted for age, gender. Model 2: Adjusted for the covariates in model 1, body mass index, systolic blood pressure, 
HbA1c, total cholesterol. 
  
Supplementary Table 5 Clinical background of all cases between positive and negative cases of each particular pathological 
findings 
 






















59.4±10.3   
(60, 53-67) 
68  
23.6±3.7   
(23.1, 21.2 -25.5) 
148.8±23.1   
(147, 134-163) 
79.1±13.0   
(80, 70-89) 
11.2±2.1   
(11.2, 9.5-12.7) 
7.4±2.0   
(7.0, 6.0-8.4) 
227.4±77.9   
(211, 177-256) 
44.9±22.5   
(42.6, 27.8 -59.6) 




 (58, 49-65) 
65  
23.8±4.2   
(23.3, 21.5 -25.8) 
141.5±20.1   
(140, 128-154) 
78.7±12.3   
(80, 70-88) 
12.6±2.2   
(12.7, 11.1-14.3) 
7.7±2.1   
(7.2, 6.2-8.9) 
210.0±67.0   
(202, 172-235) 
59.7±28.6   
(56.1, 39.5 -75.6) 
1.18±1.50   
(0.63, 0.12-1.70) 
p <0.01 # 0.42  0.60  <0.01 # 0.75  <0.01 # 0.15  0.01 # <0.01 # <0.01 # 
           
Exudative Age Gender BMI SysBP DiaBP Hb HbA1c Tcho eGFR UAlb 
+ 
58.3±10.9   
(59, 52-66) 
72  
23.7±3.9   
(23.5, 21.2 -25.6) 
148.1±21.7   
(148, 135-162) 
79.0±12.9  
 (80, 70-88) 
11.4±2.2  
 (11.4, 9.8-12.9) 





 (43.4, 30.1 -58.4) 
2.45±2.16   
(2.01, 0.89-3.19) 
- 
57.2±12.4   
(59, 49-65) 
62  
23.8±4.1   
(23.0, 21.5 -25.9) 
141.4±21.2  
 (140, 128-153) 
78.9±12.3  
 (80, 70-88) 
12.6±2.3  
(12.7, 11.1-14.2) 





 (57.3, 40.6 -76.1) 
1.18±1.66   
(0.49, 0.1-1.48) 
p 0.24  0.01 # 0.69  <0.01 # 0.93  <0.01 # 0.15  <0.05 # <0.01 # <0.01 # 
           
MesLy Age Gender BMI SysBP DiaBP Hb HbA1c Tcho eGFR Ualb 
+ 






 (150, 138-167) 
80.7±13.1   
(80, 72-88) 
11.2±2.1   
(11.2, 9.5-12.6) 
7.5±2.0   
(7.0, 6.0-8.8) 
232.0±78.0   
(211, 178-260) 
46.1±22.8  
 (43.0, 30.1 -59.9) 
2.72±2.36   
(2.26, 1.05-3.94) 
- 
57.8±12.2   
(60, 50-66) 
65  
23.7±4.2   
(23.1, 21.2 -25.6) 
139.9±19.8  
 (140, 128-150) 
77.8±12.1  
 (78, 70-86) 
12.5±2.3  
 (12.6, 11-14.2) 




58.0±28.6   
(55.5, 38.3 -73.4) 
1.19±1.51   
(0.61, 0.12-1.7) 
p 0.53  0.43  0.99  <0.01 # <0.05 # <0.01 # 0.51  <0.01 # <0.01 # <0.01 # 
 
Nodular; nodular lesion (nodular sclerosis), Exudative; exudative lesion, MesLy; mesangiolysis/microaneurysm 
BMI; body mass index, sysBP; systolic blood pressure, diaBP; diastolic blood pressure, Hb; hemoglobin, Tcho; total choresterol, 
RAS; rate of renin angiotensin system inhibitor treatment, IQR; interquartile range 
# indicates statistical significance by paired t test. 
 
 
 
